Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
Achard
J M
JM
Service de Néphrologie, Médecine Interne, Hopital Sud, Amiens, France.
Pruna
A
A
Fernandez
L A
LA
Hottelart
C
C
Mazouz
H
H
Rosa
A
A
Andrejak
M
M
Fournier
A
A
D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D020521:Stroke / Q000517:prevention & control*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II